Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BARRY A HENDIN

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1447239231
CMS profile
201693
Location
PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$355,333.39

411 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
EMD Serono, Inc. $127,052.85 63
E.R. Squibb & Sons, L.L.C. $44,106.97 27
TG Therapeutics, Inc. $41,832.20 43
Amgen Inc. $37,479.82 51
Biogen, Inc. $29,143.20 52
Genentech USA, Inc. $18,634.63 28
Novartis Pharmaceuticals Corporation $15,998.27 41
Ares Trading SA $13,440.00 1
Alexion Pharmaceuticals, Inc. $11,651.61 13
Merck KGaA $6,300.00 1
Vanda Pharmaceuticals Inc. $4,832.55 9
Celgene Corporation $3,778.63 30
BANNER LIFE SCIENCES, LLC $257.28 19
Acorda Therapeutics, Inc $146.05 8
GENZYME CORPORATION $133.24 3
Lilly USA, LLC $101.74 2
PFIZER INC. $100.92 2
Mallinckrodt Hospital Products Inc. $80.15 4
Eisai Inc. $52.10 2
ARGENX US, INC. $48.94 3
Teva Pharmaceuticals USA, Inc. $47.71 2
UCB, Inc. $28.03 2
Genentech, Inc. $22.84 1
Xeris Pharmaceuticals, Inc. $20.87 1
ANI Pharmaceuticals, Inc. $14.69 1
Amneal Pharmaceuticals LLC $14.10 1
ABBVIE INC. $14.00 1

Page 8 of 9; records 351–400 of 411 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BARRY A HENDIN

NPI 1447239231 · CMS profile ID 201693

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

PHOENIX, AZ

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 8 of 9; records 351–400 of 411 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1447239231?year=2024&recipient=provider&page=8#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BARRY A HENDIN, NPI 1447239231, CMS profile ID 201693. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 8 of 9; records 351–400 of 411 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1447239231?year=2024&recipient=provider&page=8#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). BARRY A HENDIN, NPI 1447239231, CMS profile ID 201693. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 8 of 9; records 351–400 of 411 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1447239231?year=2024&recipient=provider&page=8#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
BARRY A HENDIN, NPI 1447239231, CMS profile ID 201693, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 8 of 9; records 351–400 of 411 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1447239231?year=2024&recipient=provider&page=8#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

411 matching records · $355,333.39 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 411 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 351–400 of 411.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Celgene Corporation $21.6002/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101134970 CMS
EMD Serono, Inc. $2,923.0002/28/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120213466 CMS
TG Therapeutics, Inc. $102.8802/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136888774 CMS
Genentech USA, Inc. $19.7702/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132980585 CMS
Novartis Pharmaceuticals Corporation $9.1402/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086958117 CMS
EMD Serono, Inc. $7,933.0002/21/2024 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120213448 CMS
Celgene Corporation $2,400.0002/16/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101135036 CMS
Biogen, Inc. $21.9802/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104842168 CMS
EMD Serono, Inc. $236.9602/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120213920 CMS
EMD Serono, Inc. $596.7702/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120213924 CMS
EMD Serono, Inc. $557.6502/15/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120213926 CMS
EMD Serono, Inc. $21.0502/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120233168 CMS
Biogen, Inc. $97.4402/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104876248 CMS
Genentech USA, Inc. $28.3102/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132980583 CMS
EMD Serono, Inc. $23.9402/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120233172 CMS
Acorda Therapeutics, Inc $15.5802/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142347758 CMS
Novartis Pharmaceuticals Corporation $20.9502/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086958107 CMS
UCB, Inc. $13.1502/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143109540 CMS
ARGENX US, INC. $13.4002/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1142121539 CMS
BANNER LIFE SCIENCES, LLC $14.1302/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147028554 CMS
Novartis Pharmaceuticals Corporation $5.2502/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086958105 CMS
TG Therapeutics, Inc. $91.4202/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136888674 CMS
TG Therapeutics, Inc. $17.9802/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136888676 CMS
Vanda Pharmaceuticals Inc. $8.4901/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133905953 CMS
Biogen, Inc. $21.9801/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104868234 CMS
Amgen Inc. $6,050.0001/27/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111597858 CMS
Amgen Inc. $1,058.6801/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111597860 CMS
Amgen Inc. $14.5601/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111597862 CMS
Amgen Inc. $14.5601/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111597864 CMS
Amgen Inc. $315.2101/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111597866 CMS
Amgen Inc. $350.0001/27/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111597868 CMS
Amgen Inc. $50.0001/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111597870 CMS
Amgen Inc. $65.0001/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111597872 CMS
Amgen Inc. $46.5001/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111597848 CMS
EMD Serono, Inc. $11.3001/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1120233174 CMS
Genentech USA, Inc. $27.6201/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1132980563 CMS
Amgen Inc. $19.6401/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111597846 CMS
Xeris Pharmaceuticals, Inc. $20.8701/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1144588274 CMS
Teva Pharmaceuticals USA, Inc. $21.8801/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1151622689 CMS
Celgene Corporation $32.7101/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101134972 CMS
Celgene Corporation $109.2901/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101134974 CMS
Celgene Corporation $32.7101/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101134976 CMS
Celgene Corporation $54.5301/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101134978 CMS
Celgene Corporation $32.7201/19/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101134980 CMS
Celgene Corporation $480.5001/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101134982 CMS
Celgene Corporation $315.2701/19/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101134984 CMS
BANNER LIFE SCIENCES, LLC $5.1401/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1147028448 CMS
Biogen, Inc. $20.3701/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104809965 CMS
Novartis Pharmaceuticals Corporation $15.8601/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086958103 CMS
Novartis Pharmaceuticals Corporation $25.6601/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086958111 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $524,413.88 456
PY2020 $267,685.72 228
PY2021 $215,462.97 338
PY2022 $334,177.38 468
PY2023 $287,949.77 386
PY2024 $355,333.39 411
PY2025 $279,651.53 382

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Recipient $4,433.92 4
PY2025 Principal investigator $465,283.11 18
PY2024 Recipient $1,997.07 3
PY2024 Principal investigator $119,785.94 4
PY2023 Recipient $21,685.00 1
PY2023 Principal investigator $572,937.80 16
PY2022 Recipient $10,861.00 5
PY2022 Principal investigator $381,064.86 11
PY2021 Recipient $2,451.00 1
PY2021 Principal investigator $334,583.62 39
PY2020 Recipient $7,508.96 3
PY2020 Principal investigator $47,007.77 20
PY2019 Principal investigator $168,349.27 47

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

22 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Recipient Novartis Pharmaceuticals Corporation $783.52 11/07/2025 Covered Recipient Physician Research Publication/ Writing Support No dispute reported 06/30/2026 1190291733
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,395.16 10/08/2025 Non-covered Recipient Entity
CENTER FOR NEUROLOGY AND SPINE
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190311285
Principal investigator 1 Novartis Pharmaceuticals Corporation $878.52 10/06/2025 Non-covered Recipient Entity
PERSEVERANCE RESEARCH CENTER LLC
A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With R No dispute reported 06/30/2026 1190312943
Principal investigator 1 Novartis Pharmaceuticals Corporation $270.00 10/01/2025 Non-covered Recipient Entity
CENTER FOR NEUROLOGY AND SPINE
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis No dispute reported 06/30/2026 1190311289
Principal investigator 1 Novartis Pharmaceuticals Corporation $453.00 10/01/2025 Non-covered Recipient Entity
CENTER FOR NEUROLOGY AND SPINE
A randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis No dispute reported 06/30/2026 1190311291
Principal investigator 1 Celgene Corporation $4,500.00 09/26/2025 Non-covered Recipient Entity
Perseverance Research Center
A Phase 2, Randomized, Double-blind, Four-arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of three doses of orally administered BMS-986368, a FAAH/MAGL Inhibitor, vs. placebo for the Treatment of Spasticity in Participants with Multiple Sclerosis. No dispute reported 06/30/2026 1222306353
Recipient Novartis Pharma AG $18.62 09/25/2025 Covered Recipient Physician COMB157Q12301 No dispute reported 06/30/2026 1248109099
Principal investigator 1 EMD Serono, Inc. $345.00 09/24/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240117969
Principal investigator 1 EMD Serono, Inc. $1,700.00 09/22/2025 Non-covered Recipient Entity
Perseverance Research Center LLC
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118457
Principal investigator 1 Novartis Pharmaceuticals Corporation $423.00 09/01/2025 Non-covered Recipient Entity
PERSEVERANCE RESEARCH CENTER LLC
A Randomized, Open-label, Parallel-group, Non-inferiority Study Comparing Efficacy, Safety, and Tolerability of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis, Followed by Open-label Treatment With R No dispute reported 06/30/2026 1190312945
Recipient Novartis Pharmaceuticals Corporation $1,356.78 06/03/2025 Covered Recipient Physician Research Publication/Writing Support No dispute reported 06/30/2026 1190292383
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,068.11 05/27/2025 Non-covered Recipient Entity
Perseverance Research Center
A Phase 2, Randomized, Double-blind, Four-arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of three doses of orally administered BMS-986368, a FAAH/MAGL Inhibitor, vs. placebo for the Treatment of Spasticity in Participants with Multiple Sclerosis. No dispute reported 06/30/2026 1235994716
Principal investigator 1 EMD Serono, Inc. $1,345.00 05/22/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240117965
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,327.80 04/30/2025 Non-covered Recipient Entity
Perseverance Research Center
A Phase 2, Randomized, Double-blind, Four-arm, Placebo-controlled, Multicenter Study Assessing the Efficacy, Safety and Tolerability of three doses of orally administered BMS-986368, a FAAH/MAGL Inhibitor, vs. placebo for the Treatment of Spasticity in Participants with Multiple Sclerosis. No dispute reported 06/30/2026 1235994718
Principal investigator 1 EMD Serono, Inc. $580.00 04/09/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240117977
Principal investigator 1 EMD Serono, Inc. $1,280.00 04/09/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240117980
Principal investigator 1 EMD Serono, Inc. $410.00 03/24/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240117973
Principal investigator 1 EMD Serono, Inc. $440.00 03/24/2025 Non-covered Recipient Entity
Advarra, Inc.
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240117984
Recipient Novartis Pharma AG $2,275.00 03/18/2025 Covered Recipient Physician COMB157Q12301 No dispute reported 06/30/2026 1248109101
Principal investigator 1 EMD Serono, Inc. $23,601.00 03/06/2025 Non-covered Recipient Entity
Perseverance Research Center LLC
Effectiveness of Switching to Cladribine Tablets in Multiple Sclerosis Patients with High Disease Activity or Disease Breakthrough in a US Real-World Population (HDA Switch Study) No dispute reported 06/30/2026 1240118459
Principal investigator 1 Novartis Pharmaceuticals Corporation $57,031.73 01/31/2025 Non-covered Recipient Entity
PHOENIX NEUROLOGICAL ASSOCIATES LTD
A Randomized, Open Label, Multi-center, Active-comparator Study to Assess Efficacy, Safety & Tolerability of Ofatumumab 20mg sc Monthly Versus Continued Current Therapy in Relapsing-remitting Multiple Sclerosis After Elevation of Serum Neurofilament Light No dispute reported 06/30/2026 1190303209
Principal investigator 1 Novartis Pharmaceuticals Corporation $367,234.79 01/08/2025 Non-covered Recipient Entity
CENTER FOR NEUROLOGY AND SPINE
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190311287